Abstract
Several studies showed the inaccuracy of classical surrogate endpoints, such as progression-free survival (PFS) and objective response rate (ORR), in predicting overall survival (OS) in trials of ICI. Patients that respond to immunotherapy have longer median duration of response (mDR) than those that achieve an ORR with standard CT. We aimed to explore the validity of new surrogate endpoints that take into account ORR and mDR in the context of combination ICI trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
